Pharmaceuticals & Drugs
PPLPHARMA
Piramal Pharma Ltd.
Caution — weak structure
Setup readiness
Early Trend
- Pivot Levels
- ₹177.2-197.4
- Support Level
- ₹184.3
- Resistance
- ₹235.7
- Risk Distance
- 6.6% to stop
Reference levels for educational study only. Not a recommendation to buy or sell.
Swing Edge Intelligence
Structured setup analysis · research only
Setup status · Weak structure
Trend, relative strength and distribution characteristics suggest limited breakout quality.
Bullish factors
- Moderate distance from 52w high (-24% below).
- Price remains distant from the pivot — breakout readiness is low.
- Relative strength remains below leadership thresholds.
- 1 prior pivot rejection in last 60d (-8 pts).
- ATR 3.9%/day — healthy volatility (+4).
- BB squeeze — energy building.
- MACD positive and rising — confirmation only (no bonus).
- RSI 52 — ideal setup zone.
- OBV divergence — price flat, volume rising: hidden strength.
- Recent volume expansion — institutional participation may be returning.
- Volume flow suggests quiet institutional accumulation.
Risk factors
- Price up but OBV diverging — demand weakening
- Heavy overhead supply (60%) — trapped sellers above
Overall view
Short-term accumulation is visible, though it should be weighed against trend and RS context. Overall setup quality remains limited despite any localized compression or accumulation cues.
Setup research
PPLPHARMA — trend, RS & risk snapshot (not a trade recommendation)
Signal · context · invalidation · risk · skip reasons — research only
Positives
Building toward the pivot (15% below)
- Confirmed Stage 2 uptrend
Context & regime
- Market regime Mixed / range-bound
- Trend stage Stage 2 — tradable
- Sector Mid-pack (#20/40)
- Relative strength Lagging (RS 50)
- Trend strength Weak (ADX 19)
Negatives
This idea is wrong below ₹184.3 (-9.9% away)
Base / stop support breaks — the swing thesis is wrong below here
- Stop / base low₹184.3
- Pivot — failure re-entry below₹196.4
Risk distance
Risk ≈ ₹13.11/share from entry ₹197.4.
Reasons to skip 2
Disqualifiers that apply even if the score looks good.
- Price up but OBV diverging — demand weakening
- Heavy overhead supply (60%) — trapped sellers above
Setup metrics Latest scan
PPLPHARMA Technical Analysis & Swing Setup
Grouped structure, momentum and risk from the latest research scan.
Structure
Momentum
Risk
More scanner fields
PPLPHARMA Support & Resistance Levels
Research chart
Daily price action with pivot, support, and resistance levels from our latest scan, plus relative strength vs Nifty.
Pivot levels, support and resistance are drawn on the price chart. · Research only.
Sector RS rank · latest scan
Loading peer comparison…
Seasonality — monthly returns
How this stock moved month by month over the last ~2 years.
A rough tendency, not a reliable pattern. Research only, not advice.
AI insights
AI Insights
Generated with AIThese insights are AI-generated to support your research process and should not be treated as investment advice or a recommendation to buy or sell securities.
Sign in to unlock AI Insights
Personalised swing trade analysis powered by Gemini AI
Pattern context 52w · setup · flow
52-week range
—Stage-2 ideal band · Early recovery
Pattern highlights
Pattern signals from the latest scan
Smart money flow
Last 60 sessions · accumulation vs distribution
Setup intelligence Overhead · VCP · radar · risk
Overhead supply
Resistance ceiling above current price
Chase / failure risk
Honest read on exhaustion & extended moves
Base / VCP coil
Depth, contractions & pivot distance
Setup quality radar
Shape of the setup in one view
Peer comparison Sector peers
Sector Peer Comparison
Loading sector peers…
PPLPHARMA FAQ Common swing-trading questions
Frequently asked questions about PPLPHARMA
What are the screener observations for PPLPHARMA?
On Swing Edge's swing-setup framework, Piramal Pharma Ltd. (PPLPHARMA) currently grades C — mixed — needs patience. Building toward the pivot (15% below). Flagged today. This is educational research, not investment advice.
What are PPLPHARMA's support and resistance levels?
For PPLPHARMA, near-term support sits around ₹184.3 (the base/stop zone); overhead resistance is around ₹196.4 (the breakout pivot); the next resistance above is ₹235.7. This is educational research, not investment advice.
What is the breakout / pivot level for PPLPHARMA?
The breakout pivot for PPLPHARMA is around ₹196.4. Price is about 14.6% below the pivot and still building toward it. A breakout is typically confirmed on a close above the pivot with above-average volume. This is educational research, not investment advice.
Is PPLPHARMA above its 50-day and 200-day moving averages?
Yes — PPLPHARMA is in a confirmed Stage 2 uptrend, trading above its rising 50- and 200-day moving averages, the zone where swing setups tend to work best. This is educational research, not investment advice.
How strong is PPLPHARMA versus the market (RS rank)?
PPLPHARMA has a relative strength (RS) rank of 50 out of 100 versus the NSE universe, making it lagging the broader market on relative strength. Trend strength (ADX) reads 19, indicating a weak/choppy trend. This is educational research, not investment advice.
Answers are generated from Swing Edge's latest scan data and are for research only — not investment advice.
Prices and day-change figures use the last daily close from scan data dated 2026-06-25 — not live intraday NSE quotes.